Showing results (11-20 of 57) with videos related to
Sort By:
Pageof 6
American Journal of Therapeutics|November 5, 2010
Minimizing cardiovascular complications during the treatment of osteoarthritisAndrew Whelton, Allan GibofskyRheumatology (Oxford, England)|November 4, 2020
US rheumatologists' beliefs and knowledge about biosimilars: a surveyAllan Gibofsky, Dorothy McCabeRheumatic Diseases Clinics of North America|November 25, 2010
Musculoskeletal manifestations of thyroid diseaseSabeen Anwar, Allan GibofskyAmerican Journal of Therapeutics|May 23, 2008
Chronic pain of osteoarthritis: considerations for selecting an extended-release opioid analgesicAllan Gibofsky, Robert L BarkinPain Medicine (Malden, Mass.)|October 10, 2012
A phase 2 study evaluating the efficacy and safety of a novel, proprietary, nano-formulated, lower dose oral diclofenacGaren Manvelian, Stephen Daniels, Allan GibofskyThe American Journal of Managed Care|December 9, 2022
Provider and patient knowledge gaps on biosimilars: insights from surveysAllan Gibofsky, Colby Evans, Vibeke StrandThe American Journal of Managed Care|December 9, 2022
Overview of biosimilars for immune-mediated inflammatory diseases: summary of current evidenceVibeke Strand, Colby Evans, Allan GibofskyThe American Journal of Managed Care|December 9, 2022
Biosimilars for immune-mediated inflammatory diseases: a managed care perspectiveColby Evans, Allan Gibofsky, Vibeke StrandPostgraduate Medicine|February 9, 2012
The pharmacokinetic parameters of a single dose of a novel nano-formulated, lower-dose oral diclofenacGaren Manvelian, Stephen Daniels, Allan GibofskyCurrent Pain and Headache Reports|January 5, 2008
The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritisCarla R Scanzello, Neal K Moskowitz, Allan GibofskyPageof 6